Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

INCYTE CORPORATION (INCY)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
Latest news on INCYTE CORPORATION
05/17INCYTE : Reports from Incyte Corporation Highlight Recent Findings in Essential ..
AQ
05/17CALITHERA BIOSCIENCES : Reports First Quarter 2018 Financial Results and Recent ..
AQ
05/11MACROGENICS : Provides Update on Corporate Progress and 1st Quarter 2018 Financi..
AQ
05/04IMMUNOVACCINE INC. : Has Applied to List its Common Shares on Nasdaq, Announces ..
AQ
05/03INCYTE : Highlights Abstracts Accepted for Presentation at the 2018 ASCO Annual ..
AQ
05/03Bristol-Myers Squibb Abandons Two Phase III Trials of IDO1 Inhibitor Program
AQ
05/03INCYTE : BMS pulls the plug on Phase 3 trials of IDO1 inhibitor
AQ
05/03INCYTE CORPORATION : Report
CO
05/02INCYTE CORP : Change in Directors or Principal Officers, Submission of Matters t..
AQ
05/02BRISTOL MYERS SQUIBB : drops phase 3 trials of $800M IDO drug
AQ
05/02INCYTE CORPORATION : Report
CO
05/01INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
AQ
05/01INCYTE (NASDAQ : INCY) reported earnings of ($0.19) per share missing Walls Stre..
AQ
05/01INCYTE CORP : Results of Operations and Financial Condition, Financial Statement..
AQ
05/01INCYTE : Reports 2018 First-Quarter Financial Results and Updates on Key Clinica..
BU
05/01BMS discontinues pair of IDO1, Opdivo combo trials
AQ
05/01INCYTE : loss narrows in first quarter
AQ
05/01INCYTE CORPORATION : 1st quarter results
CO
05/01INCYTE CORPORATION : 1st quarter results
CO
04/30PHILLIPS 66 AND CONOCOPHILLIPS HAVE : See the top 25
AQ
04/26INCYTE : Investigators at Incyte Corporation Discuss Findings in Atopic Dermatit..
AQ
04/26INCYTE CORPORATION : quaterly earnings release
04/26INCYTE : to Present at Upcoming Investor Conference
BU
04/25INCYTE : Highlights Abstracts Accepted for Presentation at the 2018 ASCO Annual ..
BU
04/25IMMUNOVACCINE : and Incyte Expand Clinical Collaboration Evaluating Combination ..
AQ
04/24ELI LILLY AND : FDA committee split on Olumiant dosing
AQ
04/24INCYTE : FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but ..
PU
04/20Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Incyte Corporat..
PR
04/20FDA says Olumiant's thrombosis signal not a JAK class effect
AQ
04/19Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corpo..
PR
04/17NewLink re-evaluating Phase III plans for indoximod combo
AQ
04/13INCYTE : to Report First Quarter Financial Results
BU
04/12CHEMOURS : U.S. Patents Awarded to Inventors in Pennsylvania (April 12)
AQ
04/12INCYTE : and Merck Provide Update on Phase 3 Study of Epacadostat in Combination..
AQ
04/12NASDAQ 100 MOVERS : Ntes, incy
AQ
04/11INCYTE CORPORATION : Report
CO
04/10INCYTE : and Merck Provide Update on Phase 3 Study of Epacadostat in Combination..
AQ
04/09INCYTE : trial fails to boost Keytruda to treat melanoma
AQ
04/09NASDAQ 100 MOVERS : Incy, ntes
AQ
04/09Constellation raises $100M venture round
AQ
04/09INCYTE CORPORATION : Today’s Research Reports on Stocks to Watch: Incyte and Mer..
AC
04/09INCYTE CORPORATION (NASDAQ : INCY) Files An 8-K Other Events
AQ
04/09Biotech struggles as 2Q opens
AQ
04/09MERCK AND : Incyte, Merck Cancer Trial Failure Damages IDO Drugs Prospects
AQ
04/09INCYTE CORPORATION : Report
CO
04/06INCYTE : Synchrony, Incyte and Lockheed tumble
AQ
04/06INCYTE CORP : Other Events (form 8-K)
AQ
04/06INCYTE : Merck test failure drives some cancer-fighter stocks way down
AQ
04/06Incyte Shares Tumble After Cancer Drug Fails in Trial With Merck's Keytruda
DJ
04/06INCYTE : tumbles after epacadostat miss
AQ
04/06NASDAQ 100 MOVERS : Incy, ulta
AQ
04/06S&P 500 MOVERS : Incy, ulta
AQ
04/06INCYTE : stock plunges as key late stage study with Merck fails
AQ
04/06INCYTE CORPORATION : SEC Filing 8K
CO
04/04INCYTE : U.S. Patents Awarded to Inventors in Delaware (April 4)
AQ
04/03INCYTE CORPORATION : Report
CO
04/02Are Short-Sellers Right About Geron Corporation?
AQ
04/02INCYTE CORPORATION : Report
CO
03/31INCYTE CORPORATION : SEC Filing 10Q-1
CO
03/27INCYTE CORPORATION : Free Post Earnings Research Report: Incyte’s Quarterly Sale..
AC
03/23INCYTE : Merus and the Vall d'Hebron Institute of Oncology Announce Research Col..
AQ
03/22INCYTE : Targeted Therapy and Immuno-Oncology Portfolio to be Featured in 15 Abs..
AQ
03/21IMMUNOVACCINE : Announces Year-End 2017 Financial Results
AQ
03/19ONO PHARMACEUTICAL : Merus announces Ono Pharmaceuticals excerise of its option ..
AQ
03/15SYROS PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2017 Financial Resu..
AQ
03/15Calithera Biosciences Reports Fourth Quarter 2017 Financial Results and Recen..
AQ
03/15INCYTE : Targeted Therapy and Immuno-Oncology Portfolio to be Featured in 15 Abs..
BU
03/08INCYTE : Supports the Myeloproliferative Neoplasm Community in Honor of Rare Dis..
AQ
03/07E I DU PONT DE NEMOURS AND : U.S. Patents Awarded to Inventors in Delaware (Marc..
AQ
03/01MACROGENICS : Provides Update on Corporate Progress and 2017 Financial Results
AQ
02/28INCYTE : Supports the Myeloproliferative Neoplasm Community in Honor of Rare Dis..
BU
02/20INCYTE : to Present at Upcoming Investor Conferences
BU
02/16INCYTE : Merus Announces $55.8 Million Private Placement Offering of Common Stoc..
AQ
02/15INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
AQ
02/15INCYTE : to Present at Upcoming Investor Conference
AQ
1  2  3  4  5  6  7  8Next
Financials ($)
Sales 2018 1 783 M
EBIT 2018 195 M
Net income 2018 93,6 M
Finance 2018 927 M
Yield 2018 -
P/E ratio 2018 202,49
P/E ratio 2019 44,12
EV / Sales 2018 7,39x
EV / Sales 2019 6,21x
Capitalization 14 109 M
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | 4-Traders
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 81,0 $
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
David W. Gryska Chief Financial Officer & Executive Vice President
Reid M. Huber Chief Scientific Officer & Executive VP
Steven H. Stein Chief Medical Officer & Executive Vice President
Michael Morrissey Senior VP & Head-Global Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION-29.48%14 109
CELLTRION, INC.--.--%31 419
IQVIA HOLDINGS INC4.83%21 259
LONZA GROUP1.41%20 379
NEKTAR THERAPEUTICS42.83%14 033
ALNYLAM PHARMACEUTICALS, INC.-20.66%9 948